Detection of Biochemically Recurrent Prostate Cancer with [<sup>18</sup>F]DCFPyL PET/CT: An Updated Systematic Review and Meta-Analysis with a Focus on Correlations with Serum Prostate-Specific Antigen Parameters
Mohammad S. Sadaghiani,
Sara Sheikhbahaei,
Abdullah Al-Zaghal,
Lilja B. Solnes,
Martin G. Pomper,
Jorge D. Oldan,
Gary A. Ulaner,
Michael A. Gorin,
Steven P. Rowe
Affiliations
Mohammad S. Sadaghiani
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Sara Sheikhbahaei
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Abdullah Al-Zaghal
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Lilja B. Solnes
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Martin G. Pomper
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Jorge D. Oldan
Department of Radiology, University of North Carolina, Chapel Hill, NC 27599, USA
Gary A. Ulaner
Molecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, CA 92633, USA
Michael A. Gorin
Milton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Steven P. Rowe
Department of Radiology, University of North Carolina, Chapel Hill, NC 27599, USA
[18F]DCFPyL is increasingly used for prostate-specific membrane antigen (PSMA) mediated imaging of men with biochemically recurrent prostate cancer (BRPCa). In this meta-analysis, which is updated with the addition of multiple new studies, including the definitive phase III CONDOR trial, we discuss the detection efficiency of [18F]DCFPyL in BRPCa patients. PubMed was searched on 29 September 2022. Studies evaluating the diagnostic performance of [18F]DCFPyL among patients with BRPCa were included. The overall pooled detection rate with a 95% confidence interval (95% CI) was calculated among all included studies and stratified among patients with PSA ≥ 2 vs. 18F]DCFPyL in men with BRPCa has trended down since a previous meta-analysis, which may reflect increasingly stringent inclusion criteria for studies over time.
